Medical Device News Magazine

Advanced Biological Laboratories Receives CE-IVD Registration for its SANGER and for its NGS DeepChek®-HIV Genotyping Drug Resistance Assays

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Advanced Biological Laboratories (ABL) announced today the CE-IVD marking of its DeepChek®-HIV assays, is now available for in-vitro diagnostics.

Intended to be used on HIV-1 Group M viruses from patients diagnosed with HIV infection, the assays deliver standardized, open, and flexible solution suited to clinical settings performing sequencing through Capillary Electrophoresis and Next Generation Sequencing (NGS) systems.

The DeepChek®-HIV CE IVD Assays are covering respectively the Protease / Reverse Transcriptase and the Integrase regions of the virus and are intended to be used from input RNA extracted from plasma, serum or whole blood samples. Both assays are highly sensitive and have been validated to process clinical samples as low as 1,000 copies/mL with outstanding performances (100% agreement of analytical reproducibility and repeatability, 100% clinical reproducibility, 99% clinical sensitivity) in all three regions.

Open and flexible, the DeepChek®-HIV CE IVD Assays is a unique and versatile system that can be used under a large variety of laboratory throughput configurations.

“Obtaining CE IVD marking for our DeepChek®-HIV assays will allow virology labs to access a unique and innovative technology, for HIV genotyping diagnostics. ABL will keep standardizing its entire portfolio of applications in virology and microbiology following European and International guidelines to improve the management of patients suffering from chronic diseases on a worldwide basis,” said Dr. Chalom Sayada, CEO of ABL.

HIV remains a major public health threat throughout developed and developing countries. “We are extremely pleased to offer a growing portfolio of standardized diagnostics applications for infectious diseases to our clients and partners, around RNA or DNA detection (UltraGene®), and for sequencing-based genotyping (DeepChek®),” explained Dimitri Gonzalez, Head of the Diagnostics division of ABL.

“The DeepChek®-HIV CE IVD Assays are very flexible and perfectly suited to a broad range of settings running either Sanger or NGS workflows. They have for instance been validated together with the DeepChek® Library Preparation assays on several NGS platforms from Illumina including the iSeq100 instrument,” added Dr. Sofiane Mohamed, Head of Laboratory Research and Development.

“The regulatory efforts ABL has engaged, for certifying its molecular diagnostics applications in continuation of the workaround SARS-CoV-2, needed to be taken for the potential benefits of safety and efficacy to the HIV patients,” added Mr. Ronan Boulmé, Governance, Risk and Compliance Manager of the ABL Group.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.